Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis

<div>Forest plot for intervention with PI3K inhibitor versus control for objective response rate (a), 6-month progression-free survival (b), 1 year progression-free survival (c), and hazard ratio for progression-free survival (d) in the PIK3CA-mutated subgroup and the PIK3CA wild-type subgroup patients with breast cancer.</div>

BioMed Research International

fig2

Figure 2

Figure 2: Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis 

Figure 2 | Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis 